中藥創(chuàng)新是中藥現(xiàn)代化、國(guó)際化的靈魂。如何借助現(xiàn)代生命科學(xué)和醫(yī)藥學(xué)最新理論技術(shù)實(shí)現(xiàn)創(chuàng)新中藥研發(fā)是中藥研究中亟待解決的關(guān)鍵問(wèn)題?；谖覈?guó)近百年的中藥現(xiàn)代研究的歷史和經(jīng)驗(yàn)，借鑒西方天然藥物研發(fā)的思路，以中藥創(chuàng)新研究中的幾個(gè)成功的先例，總結(jié)和歸納了創(chuàng)新中藥研究的6種主要模式：青蒿素模式、培養(yǎng)基模式、GBE761-Veregen模式、PHY906模式、復(fù)方丹參滴丸模式、PC-SPES模式，評(píng)述了各個(gè)模式在創(chuàng)新中藥研究中的應(yīng)用、特點(diǎn)、優(yōu)缺點(diǎn)等，并對(duì)其發(fā)展前景進(jìn)行了展望。

The innovation of Chinese materia medica (CMM) is the soul of traditional Chinese medicine (TCM) modernization and internationalization. The application of modern theories and techniques in life sciences and medicine to innovative CMM research remains to be an urgent issue to be solved in TCM research area. This paper summarizes and generalizes six main R&D models for CMM innovation according to the nearly one century of history and experiences accumulated in TCM research in China and referencing to the idea and philosophy of natural product study in Western countries as well. The nomenclature of these models is based on several successful drug discovery examples in TCM, such as the artemisinin model, the culture medium model, the GBE761-Veregen model, the PHY906 model, the Compound Danshen Dripping Pills model, and the PC-SPES model. The application, characteristics, advantages, disadvantages, and the development prospect of each model in TCM R&D have been reviewed.

澳門(mén)大學(xué)研究基金資助（SRG013-ICMS11-CXP）